NeoGenomics (NEO) announced the PanTracer LBx test has received coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program under LCD – MolDX: Plasma-Based Genomic Profiling in Solid Tumors. This decision will enable Medicare patients to receive coverage for PanTracer LBx, a blood-based genomic profiling test designed to support therapy selection and clinical trial enrollment in patients with advanced solid tumors. The LBx test is performed in our CLIA-certified laboratory in California.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target raised to $13 from $12 at Piper Sandler
- NeoGenomics Faces High-Stakes Risk as Test Reliability and Diagnostic Errors Threaten Reputation and Legal Exposure
- NeoGenomics Earnings Call Signals Growth With Caveats
- NeoGenomics: Solid Core Growth, Aligned 2026 Outlook, and RaDaR Expansion Support Buy Rating and Higher Price Target
- Midday Fly By: Warner Bros. reopens Paramount talks